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Table 1
Variables
GRACE
<108 points
GRACE
108-140 points
GRACE
>140 points p
Age, years 48.338.77z 55.528.87z,yy 67.9711.7*,y <0.001
Men, n (%) 16 (76.2%) 43 (89.6%) 22 (68.8%) 0.063
BMI, kg/m2 28.063.70 27.274.09 26.403.20 0.449
HT, n (%) 9 (42.9%) 13 (21.7%) 20 (62.5%) 0.007
DM, n (%) 3 (14.3%) 11 (22.9%) 9 (28.1%) 0.501
HPL, n (%) 11 (52.4%) 13 (27.1%) 10 (31.3%) 0.116
Smoker,
n (%)
15 (71.4%) 28 (58.3%) 14 (43.8%) 0.130
Glucose,
(mg/dl)
162.864.0 151.452.1 192.2131.4 0.745
WBC, cells/ml 124593041 122693643 117874113 0.492
Neutrophil, % 54.6412.15y,z 65.595.82*,z 79.25.25*,y <0.001
Lymphocyte, % 37.426.42y,z 25.704.47*,z 13.444.32*,y <0.001
NLR 1.520.50y,z 2.650.65*,z 6.481.99*,y <0.001
TroponinT,
ng/dl
0.180.64z 0.631.86z,** 1.061.57*,y <0.001
Demographic and biochemical characteristics of patients in GRACE risk score groups
(Abbreviations: BMI, body mass index; HT, hypertension; DM, diabetes mellitus; HPL, hyper-
lipidemia; WBC, white blood cell; NLR, neutrophil/lymphocyte ratio y p<0.001 compared with
GRACE 108-140 points, z p<0.001 compared with GRACE>140 points, * p<0.001 compared
with GRACE<108 points, ** p¼0.007 compared with GRACE<108 points, yy p¼0.01
compared with GRACE<108 points)
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Variables Odds ratio CI 95% P
NLR 3.63 1.31-10.04 0.013
_In hospital GRACE
death point
1.03 0.98-1.07 0.2
Glucose 1 0.98-1.01 0.98
Troponin T 0.978 0.461-2.078 0.95
Multivariate logistic regression analyses in hospital cardiac events
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Background and Purpose: In the setting of unstable angina/non-ST-segment
elevation acute coronary syndromes (UA/NSTEMI- ACS), diabetes mellitus particu-
larly were found to be an independent predictor of mortality. We present the treatment
trends of NSTEMI- ACS in diabetic patients in King Abdulaziz Medical city National
Guard Hospital (KAMC) in Jeddah in comparison to the whole Kingdom of
Saudi Arabia (KSA). Data are derived from the results of Multicenter International
Diabetes – Acute Coronary Syndromes (MIDAS) study.
Design: Diabetic patients presenting with UA/NSTEMI- ACS where enrolled into the
study at the time of admission to the emergency/coronary care department.
A total of 3624 patients were enrolled in several countries; 35 from KAMCamong
total of 142 from KSA.
Results: The patients enrolled were 94% type 2 DM in KSA, while in Jeddah,the
percentage was 100% and theyhad more prevalent high risk factors.
Glycoprotein IIb/IIIa inhibitorsweremore utilized appropriately in Jeddah, particularly
in the elderly, in comparison to thewholeKSA,but less than the recommendedguidelines.
While the use of Clopedogril / Ticlopidine was similarly high in both populations.
Conclusions: The non-invasive approach did not affect the trends of treatment in
KAMC. GP IIb/IIIa inhibitors are underutilized in KAMC; however it was more
utilized than the whole KSA. Clopedogril / Ticlopidineuse were optimal in both
location.LS C23
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Decreased Hepcidin-25 Level as a Predictor of Poor Prognosis in Acute Coronary
Syndrome Patients
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Background: The peptide hormone hepcidin-25 is known as a type-II acute phase
protein in patients with chronic inﬂammatory conditions and it has a central role in iron
homeostasis as well as in anemia, inﬂammation and hypoxia. Atherosclerosis is widely
accepted as a chronic inﬂammatory disease. Herein, we evaluated whether hepcidin-25
level has a prognostic role in patients with acute coronary syndromes (ACS).
Material-Method: Forty-eight patients with ACS admitted to the coronary care unit
of our hospital were included in Group 1, 19 patients without any signiﬁcant coronary
artery disease were included in Group 2 and 20 healthy subjects as control were
included in Group 3. Serum hepcidin-25 levels were measured with Hepcidin
ELISA kits.
Results: Patients with ACS were followed-up for up to 24 months after admission
with regard to cardiac events including death, myocardial infarction and revascularisa-
tion. There was no signiﬁcant difference between the baseline biochemical and clinical
characteristics of Group 1 and Group 2. Hepcidin-25 level was lower in Group 1 when
compared with other Groups (19274 ng/mL, 296104 ng/mL, 303.892.1,
p<0.01). Hepcidin-25 level was found signiﬁcantly lower in patients who developed
a cardiac event compared to those who did not (14078 ng/ml vs 20874 ng/ml,
p<0.05) but ferritin and hsCRP were similar.
Conclusions: Reduced serum hepcidin-25 levels might predict poor outcome in
patients with ACS.C24 JACC Vol 62/18/Suppl C j October 26–29, 2013 j TSC Abstracts/ORALS
